Printer Friendly

Asana BioSciences Starts Phase 2 Evaluation of ASN002 in NHL, CLL and MF.

M2 PHARMA-May 31, 2017-Asana BioSciences Starts Phase 2 Evaluation of ASN002 in NHL, CLL and MF

(C)2017 M2 COMMUNICATIONS

- One of US-based biopharmaceutical company Asana BioSciences, LLC's lead molecules, ASN002, has completed the dose escalation phase in patients with Non-Hodgkin's Lymphoma and is now being investigated in the Phase 2 part of a multicenter trial in multiple hematological indications including NHL, Chronic Lymphocytic Leukemia, and Myelofibrosis, the company said.

ASN002 is a potent inhibitor of spleen tyrosine kinase and Janus kinases.

These kinases are involved in both cytokine production and signaling and have been implicated in the pathogenesis of various types of lymphomas, solid tumors, myeloproliferative and autoimmune disorders.

ASN002 shows robust anti-proliferative activity in a broad panel of lymphoma/leukemia cell lines, including ibrutinib-resistant cell lines.

Updated Phase 1 data including pharmacokinetics, safety and early clinical activity supporting the Phase 2 dose recommendation will be presented at the ASCO annual meeting being held in Chicago from June 2-6, 2017.

In addition, Asana will present Phase 1 safety and preliminary efficacy data for ASN001, its novel and highly selective CYP17 inhibitor that does not require prednisone co-administration, in patients with metastatic castration-resistant prostate cancer.

Asana BioSciences, an independent member of the Amneal Alliance of Companies, is an oncology focused research and development company based in Lawrenceville, NJ, involved in the discovery and development of new chemical and biological entities.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 31, 2017
Words:241
Previous Article:Gilead Touts Positive Phase 3 Data on Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV-1.
Next Article:Roche Australia's Valium recalled following evidence of tampering.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |